- About Us
- Products in Development
Our publicly available stock is traded on the NASDAQ Capital Market.
You must contact a registered broker to invest in Evofem (EVFM) stock.
Evofem became a public company through a reverse merger with Neothetics, Inc., which closed January 17, 2018.
Royal Bank of Canada (or RBC)
Evofem, Inc. was incorporated in 2009. However, Evofem, Inc.'s ultimate parent company Evofem Biosciences, Inc. was incorporated in 2015
Evofem headquarters are in San Diego, CA.
There are currently 17,757,165 shares outstanding
Philadelphia Stock Transfer
Please refer to the SEC filings webpage of the Investor section of our website.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Evofem Biosciences develops and anticipates commercializing innovative products to address unmet needs in women's sexual and reproductive health.
Plans for reporting of Evofem's quarterly and annual financial results will be announced in advance; please check the Events and Presesntations section within the Investor section of our website for details, or sign up for news alerts to be notifiedby email.
The dates for stockholder meetings are determined by the Board of Directors and will be made available on our website under “Corporate Governance.” Proxy materials and annual reports will be made available online or mailed at request.
Evofem is on a calendar year that ends December 31.
In the event quarterly and/or annual financial results calls or webcasts are scheduled, access information will be disclosed in a press release and included in the Events and Presentations section within the Investor relations section of our website.
Please contact Amy Raskopf at [email protected] or 858.550.1900 x 167.
You can sign up for e-mail alerts notifying you of new press releases, SEC filings or corporate actions and events on the “Investor Contacts and Alerts” page of the Investor section of our website.
Evofem has approximately 25 employees.